Australia's Cyclopharm rises on deal with University of Pennsylvania Health System
23/03/2026 02:35
** Shares of Cyclopharm CYC.AX rise as much as 4.9% to A$0.755, their highest level since March 13 ** Radiopharmaceuticals maker secures multi-site agreement with University of Pennsylvania Health System ** The agreement provides for two immediate Technegas installations at the Hospital of the University of Pennsylvania and at the Perelman Center for Advanced Medicine, others ** Technegas is co's diagnostic lung imaging equipment ** Stock down 23.5% this year, including the day's move (Reporting by Sherin Sunny in Bengaluru) ((Sherin.Sunny@thomsonreuters.com))
Recent news on Cyclopharm
See all newsAustralia's Cyclopharm rises after Chinese medical groups back its Technegas
Australia's Cyclopharm gains most in 8-months on Technegas rollout deal
Australia's Cyclopharm rises on HY revenue forecast
Brief: Cyclopharm Forecasts 1H Global Revenue Of A$17.1 Million
Brief: Cyclopharm Says David Heaney To Retire As Non-Executive Chair